Cargando…

Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer

Intertumor heterogeneity has been proposed as a potential mechanism to account for variability in cognitive performance in women diagnosed with breast cancer. The purpose of this study was to explore associations between variation in pathologic tumor features (PTFs) and variability in preadjuvant th...

Descripción completa

Detalles Bibliográficos
Autores principales: Koleck, Theresa A., Bender, Catherine M., Sereika, Susan M., Ryan, Christopher M., Ghotkar, Puja, Brufsky, Adam M., Jankowitz, Rachel C., McAuliffe, Priscilla F., Clark, Beth Z., Conley, Yvette P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313647/
https://www.ncbi.nlm.nih.gov/pubmed/28083945
http://dx.doi.org/10.1002/cam4.964
_version_ 1782508379984363520
author Koleck, Theresa A.
Bender, Catherine M.
Sereika, Susan M.
Ryan, Christopher M.
Ghotkar, Puja
Brufsky, Adam M.
Jankowitz, Rachel C.
McAuliffe, Priscilla F.
Clark, Beth Z.
Conley, Yvette P.
author_facet Koleck, Theresa A.
Bender, Catherine M.
Sereika, Susan M.
Ryan, Christopher M.
Ghotkar, Puja
Brufsky, Adam M.
Jankowitz, Rachel C.
McAuliffe, Priscilla F.
Clark, Beth Z.
Conley, Yvette P.
author_sort Koleck, Theresa A.
collection PubMed
description Intertumor heterogeneity has been proposed as a potential mechanism to account for variability in cognitive performance in women diagnosed with breast cancer. The purpose of this study was to explore associations between variation in pathologic tumor features (PTFs) and variability in preadjuvant therapy cognitive performance in postmenopausal women newly diagnosed with early‐stage breast cancer. Participants (N = 329) completed a comprehensive battery of neuropsychological tests to evaluate cognitive performance after primary surgery but prior to initiation of adjuvant anastrozole±chemotherapy. PTF data were abstracted from medical records. Robust multiple linear regression models were fit to estimate associations between individual PTFs and the cognitive function composite domain scores. All models controlled for age, estimated intelligence, and levels of depressive symptoms, anxiety, fatigue, and pain. Diagnosis of a HER2‐positive tumor contributed to poorer verbal (b = −0.287, P = 0.018), visual (b = −0.270, P = 0.001), and visual working (b = −0.490, P < 0.001) memory performance compared to diagnosis of a HER2‐negative tumor. Similarly, as HER2 immunohistochemistry classification score increased, verbal (b = −0.072, P = 0.093), visual (b = −0.081, P = 0.003), and visual working (b = −0.170, P < 0.001) memory performance score decreased. Associations with performance were also noted between location, focality/centricity, hormone receptor expression, cellular proliferation (i.e., Ki67), and Oncotype DX (®) Breast Cancer Assay Recurrence Score(®).) Our results suggest that certain PTFs related to more aggressive tumor phenotypes or inferior breast cancer prognosis may be implicated in poorer preadjuvant therapy cognitive performance. Follow‐up studies that include a cognitive assessment before primary surgery should be conducted to further delineate the role of intertumor heterogeneity on cognitive performance.
format Online
Article
Text
id pubmed-5313647
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-53136472017-02-24 Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer Koleck, Theresa A. Bender, Catherine M. Sereika, Susan M. Ryan, Christopher M. Ghotkar, Puja Brufsky, Adam M. Jankowitz, Rachel C. McAuliffe, Priscilla F. Clark, Beth Z. Conley, Yvette P. Cancer Med Clinical Cancer Research Intertumor heterogeneity has been proposed as a potential mechanism to account for variability in cognitive performance in women diagnosed with breast cancer. The purpose of this study was to explore associations between variation in pathologic tumor features (PTFs) and variability in preadjuvant therapy cognitive performance in postmenopausal women newly diagnosed with early‐stage breast cancer. Participants (N = 329) completed a comprehensive battery of neuropsychological tests to evaluate cognitive performance after primary surgery but prior to initiation of adjuvant anastrozole±chemotherapy. PTF data were abstracted from medical records. Robust multiple linear regression models were fit to estimate associations between individual PTFs and the cognitive function composite domain scores. All models controlled for age, estimated intelligence, and levels of depressive symptoms, anxiety, fatigue, and pain. Diagnosis of a HER2‐positive tumor contributed to poorer verbal (b = −0.287, P = 0.018), visual (b = −0.270, P = 0.001), and visual working (b = −0.490, P < 0.001) memory performance compared to diagnosis of a HER2‐negative tumor. Similarly, as HER2 immunohistochemistry classification score increased, verbal (b = −0.072, P = 0.093), visual (b = −0.081, P = 0.003), and visual working (b = −0.170, P < 0.001) memory performance score decreased. Associations with performance were also noted between location, focality/centricity, hormone receptor expression, cellular proliferation (i.e., Ki67), and Oncotype DX (®) Breast Cancer Assay Recurrence Score(®).) Our results suggest that certain PTFs related to more aggressive tumor phenotypes or inferior breast cancer prognosis may be implicated in poorer preadjuvant therapy cognitive performance. Follow‐up studies that include a cognitive assessment before primary surgery should be conducted to further delineate the role of intertumor heterogeneity on cognitive performance. John Wiley and Sons Inc. 2017-01-13 /pmc/articles/PMC5313647/ /pubmed/28083945 http://dx.doi.org/10.1002/cam4.964 Text en © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Koleck, Theresa A.
Bender, Catherine M.
Sereika, Susan M.
Ryan, Christopher M.
Ghotkar, Puja
Brufsky, Adam M.
Jankowitz, Rachel C.
McAuliffe, Priscilla F.
Clark, Beth Z.
Conley, Yvette P.
Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer
title Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer
title_full Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer
title_fullStr Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer
title_full_unstemmed Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer
title_short Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer
title_sort associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313647/
https://www.ncbi.nlm.nih.gov/pubmed/28083945
http://dx.doi.org/10.1002/cam4.964
work_keys_str_mv AT kolecktheresaa associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer
AT bendercatherinem associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer
AT sereikasusanm associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer
AT ryanchristopherm associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer
AT ghotkarpuja associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer
AT brufskyadamm associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer
AT jankowitzrachelc associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer
AT mcauliffepriscillaf associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer
AT clarkbethz associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer
AT conleyyvettep associationsbetweenpathologictumorfeaturesandpreadjuvanttherapycognitiveperformanceinwomendiagnosedwithbreastcancer